靶向溶酶体降解与生长信号双功能的新策略
本研究通过筛选新型二聚抗疟化合物,发现二聚奎纳克林(DQ)可同时抑制mTOR和自噬,其连接子中央氮甲基化增强溶酶体定位与效力。原位光亲和下拉鉴定棕榈酰蛋白硫酯酶1(PPT1)为DQ661的分子靶点,PPT1抑制通过棕榈酰化蛋白快速积累同时损害mTOR和溶酶体分解代谢。DQ661在黑色素瘤、胰腺癌和结直肠癌小鼠模型中抑制体内肿瘤生长,并可安全与化疗联合。
要点
- 二聚奎纳克林(DQ)可同时抑制mTOR和自噬,连接子中央氮甲基化增强溶酶体定位与效力。
- PPT1被鉴定为DQ661的分子靶点,PPT1抑制通过棕榈酰化蛋白积累损害mTOR和溶酶体分解代谢。
- DQ661在黑色素瘤、胰腺癌和结直肠癌小鼠模型中抑制肿瘤生长,可安全联合化疗。
核心结论
- 溶酶体导向的PPT1抑制剂代表一种同时靶向mTORC1和溶酶体分解代谢的癌症治疗新方法。
研究设计与样本
- 研究筛选新型二聚抗疟化合物,通过原位光亲和下拉鉴定分子靶点,并在黑色素瘤、胰腺癌和结直肠癌小鼠模型中评估体内肿瘤生长。
主要发现
- 二聚奎纳克林(DQ)被鉴定为强效抗癌化合物,可同时抑制mTOR和自噬。
- DQ连接子的中央氮甲基化增强溶酶体定位和效力。
- 原位光亲和下拉鉴定棕榈酰蛋白硫酯酶1(PPT1)为DQ661的分子靶点。
- PPT1抑制通过棕榈酰化蛋白的快速积累同时损害mTOR和溶酶体分解代谢。
- DQ661抑制黑色素瘤、胰腺癌和结直肠癌小鼠模型的体内肿瘤生长,并可安全与化疗联合。
关键数值与推荐
- 氯喹或奎纳克林等抗疟化合物用作溶酶体抑制剂,但不能抑制mTOR信号,且其分子靶点尚未确定。
临床怎么用
- 溶酶体导向的PPT1抑制剂可作为同时靶向mTORC1和溶酶体分解代谢的新策略用于癌症治疗。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Lysosomes serve dual roles in cancer metabolism, executing catabolic programs (i.e., autophagy and macropinocytosis) while promoting mTORC1-dependent anabolism. Antimalarial compounds such as chloroquine or quinacrine have been used as lysosomal inhibitors, but fail to inhibit mTOR signaling. Further, the molecular target of these agents has not been identified. We report a screen of novel dimeric antimalarials that identifies dimeric quinacrines (DQ) as potent anticancer compounds, which concurrently inhibit mTOR and autophagy. Central nitrogen methylation of the DQ linker enhances lysosomal localization and potency. An in situ photoaffinity pulldown identified palmitoyl-protein thioesterase 1 (PPT1) as the molecular target of DQ661. PPT1 inhibition concurrently impairs mTOR and lysosomal catabolism through the rapid accumulation of palmitoylated proteins. DQ661 inhibits the in vivo tumor growth of melanoma, pancreatic cancer, and colorectal cancer mouse models and can be safely combined with chemotherapy. Thus, lysosome-directed PPT1 inhibitors represent a new approach to concurrently targeting mTORC1 and lysosomal catabolism in cancer.Significance: This study identifies chemical features of dimeric compounds that increase their lysosomal specificity, and a new molecular target for these compounds, reclassifying these compounds as targeted therapies. Targeting PPT1 blocks mTOR signaling in a manner distinct from catalytic inhibitors, while concurrently inhibiting autophagy, thereby providing a new strategy for cancer therapy. Cancer Discov; 7(11); 1266-83. ©2017 AACR.See related commentary by Towers and Thorburn, p. 1218This article is highlighted in the In This Issue feature, p. 1201.
引用
- Rebecca VW, Nicastri MC, McLaughlin N, et al. A Unified Approach to Targeting the Lysosome's Degradative and Growth Signaling Roles. Cancer Discov. 2017. PMID: 28899863. doi:10.1158/2159-8290.CD-17-0741
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。